Literature DB >> 27882779

Ipilimumab: from preclinical development to future clinical perspectives in melanoma.

Paul Letendre1, Varun Monga1, Mohammed Milhem1, Yousef Zakharia1.   

Abstract

The arsenal for the treatment of metastatic melanoma is limited. A new approach to therapy using checkpoint blockade has improved overall survival in this patient population. Ipilimumab a CTLA-4 monoclonal antibody is a first in class drug that has pioneered this revolution. In this review, the authors provide an account of the different stages that led to the development of ipilimumab, its approval in the clinical setting for the treatment of advanced melanoma and ongoing investigations of combinatorial immune therapy.

Entities:  

Keywords:  CTLA-4 antibody; checkpoint blockade; immunomodulatory; ipilimumab; melanoma; metastatic melanoma

Mesh：

Substances：

Year:  2016        PMID： 27882779      PMCID： PMC5618953          DOI： 10.2217/fon-2016-0385

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  49 in total

Review 1.  CD28-mediated co-stimulation: a quantitative support for TCR signalling.

Authors:  Oreste Acuto; Frédérique Michel
Journal:  Nat Rev Immunol       Date:  2003-12       Impact factor: 53.106

Review 2.  Immunostimulatory monoclonal antibodies for cancer therapy.

Authors:  Ignacio Melero; Sandra Hervas-Stubbs; Martin Glennie; Drew M Pardoll; Lieping Chen
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

Review 3.  Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.

Authors:  Al-Ola Abdallah; Aline Herlopian; Rahul Ravilla; Meghana Bansal; Sowmya Chandra-Reddy; Fade Mahmoud; Shirley Ong; Murat Gokden; Laura Hutchins
Journal:  J Oncol Pharm Pract       Date:  2015-02-23       Impact factor: 1.809

4.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

5.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

6.  Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.

Authors:  Jeffrey S Weber; Reinhard Dummer; Veerle de Pril; Celeste Lebbé; F Stephen Hodi
Journal:  Cancer       Date:  2013-02-07       Impact factor: 6.860

Review 7.  Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

Authors:  Lawrence Fong; Eric J Small
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

8.  Phase I/II study of ipilimumab for patients with metastatic melanoma.

Authors:  Jeffrey S Weber; Steven O'Day; Walter Urba; John Powderly; Geoff Nichol; Michael Yellin; Jolie Snively; Evan Hersh
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

Authors:  D McDermott; J Haanen; T-T Chen; P Lorigan; S O'Day
Journal:  Ann Oncol       Date:  2013-08-13       Impact factor: 32.976
View more
  5 in total

Review 1.  Humanized mice for immune checkpoint blockade in human solid tumors.

Authors:  Henry Yip; Carl Haupt; Grace Maresh; Xin Zhang; Li Li
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

Review 2.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

Authors:  Isabel Corraliza-Gorjón; Beatriz Somovilla-Crespo; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

Review 3.  Small-Molecule Targets in Tumor Immunotherapy.

Authors:  Hui-Fang Zhu; Yan Li
Journal:  Nat Prod Bioprospect       Date:  2018-07-05

Review 4.  Development of oncolytic virotherapy: from genetic modification to combination therapy.

Authors:  Qiaoshuai Lan; Shuai Xia; Qian Wang; Wei Xu; Haiyan Huang; Shibo Jiang; Lu Lu
Journal:  Front Med       Date:  2020-03-07       Impact factor: 4.592

Review 5.  Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment.

Authors:  Yushuai Liu; Yuanyuan Geng; Beilei Yue; Pui-Chi Lo; Jing Huang; Honglin Jin
Journal:  Front Immunol       Date:  2022-01-17       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.